{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:03:01Z","timestamp":1792605781241,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloidosis is a complex and rare disease requiring specialized, multidisciplinary care to effectively manage its diverse manifestations. Existing evidence underscores the benefits of such care, linked to improved patient outcomes and clinician satisfaction. With the rising incidence of amyloidosis diagnoses and rapid advancements in treatment, the need for coordinated, expert-led care is increasing. However, implementing these centers is challenging due to resource allocation and inter-specialty collaboration. While resource allocation is a known hurdle, there has not been a comprehensive review of all the barriers and facilitators to establishing these clinics. This scoping review aims to identify the barriers and facilitators related to the implementation of coordinated, multidisciplinary specialty care clinics in amyloidosis management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An electronic search was conducted in Medline, Embase, and CINAHL for studies published in English from 2013 to 2023, supplemented by a grey literature search. The inclusion criteria focused on studies discussing multidisciplinary clinical environments for amyloidosis care, particularly light-chain (AL) and transthyretin amyloidosis (TTR). Exclusion criteria included books, opinion pieces, dissertations, and conference abstracts. Data were analyzed and synthesized using a narrative synthesis approach, guided by the Consolidated Framework for Implementation Research (CFIR), and reported according to PRISMA-ScR guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search resulted in 1547 findings. After screening with Covidence, 7 papers were included in the final review. Independent reviewers screened and extracted the papers. Key facilitators identified include access to experts, adequate staffing, secure funding, partnerships with patient advocacy groups, and robust processes for multidisciplinary communication. Barriers primarily relate to the complexity of care, a lack of standardized protocols, difficulties in communication and coordination between providers, and challenges in training and maintaining knowledgeable care providers. The review also revealed significant gaps in existing research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review enhances understanding of the barriers and facilitators in establishing amyloidosis specialty clinics. Addressing these barriers and leveraging facilitators are crucial for shaping the future of amyloidosis care. These insights support a model for implementing integrated care for this growing patient population and highlight the need for further research to support policy development and effective implementation of these specialized clinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-12520-3","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:39:08Z","timestamp":1742503148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research"],"prefix":"10.1186","volume":"25","author":[{"given":"Mary","family":"O\u2019Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahab","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archanaa","family":"Krisnagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene H.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"12520_CR1","doi-asserted-by":"publisher","unstructured":"Abdulgawad AA, Nicholson M, Goubran H. Amyloidosis: Clinical Manifestations and Treatment. In: Ragab G, Quartuccio L, Goubran H, editors. Paraproteinemia and Related Disorders. Cham: Springer International Publishing; 2022:113\u201325. Available from: https:\/\/doi.org\/10.1007\/978-3-031-10131-1_8. Cited 2024 May 7.","DOI":"10.1007\/978-3-031-10131-1_8"},{"issue":"4","key":"12520_CR2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512\u201326.","journal-title":"Eur J Heart Fail."},{"issue":"5","key":"12520_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00486-4","volume":"11","author":"R Al Hamed","year":"2021","unstructured":"Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive Review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):1\u201313.","journal-title":"Blood Cancer J"},{"issue":"6","key":"12520_CR4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","volume":"97","author":"MA Gertz","year":"2022","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818\u201329.","journal-title":"Am J Hematol"},{"issue":"4","key":"12520_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hlc.2019.11.019","volume":"29","author":"NK Bart","year":"2020","unstructured":"Bart NK, Thomas L, Korczyk D, Atherton JJ, Stewart GJ, Fatkin D. Amyloid Cardiomyopathy. Heart Lung Circ. 2020;29(4):575\u201383.","journal-title":"Heart Lung Circ"},{"key":"12520_CR6","doi-asserted-by":"crossref","unstructured":"Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;1(2):e000364.","DOI":"10.1161\/JAHA.111.000364"},{"issue":"14","key":"12520_CR7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and New Therapeutic Options. J Clin Oncol. 2011;29(14):1924\u201333.","journal-title":"J Clin Oncol"},{"issue":"3","key":"12520_CR8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","volume":"36","author":"NM Fine","year":"2020","unstructured":"Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society\/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Can J Cardiol. 2020;36(3):322\u201334.","journal-title":"Can J Cardiol"},{"issue":"4","key":"12520_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/13506129.2019.1640672","volume":"26","author":"A Staron","year":"2019","unstructured":"Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. A new era of amyloidosis: the trends at a major US referral centre. Amyloid. 2019;26(4):192\u20136.","journal-title":"Amyloid"},{"issue":"1","key":"12520_CR10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022;17(1):278.","journal-title":"Orphanet J Rare Dis"},{"issue":"38","key":"12520_CR11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879\u201387.","journal-title":"Eur Heart J"},{"issue":"23","key":"12520_CR12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hag\u00e8ge AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826\u201334.","journal-title":"Eur Heart J"},{"issue":"38","key":"12520_CR13","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585\u201394.","journal-title":"Eur Heart J"},{"issue":"6","key":"12520_CR14","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.15420\/cfr.2019.16","volume":"7","author":"SH Klaassen","year":"2020","unstructured":"Klaassen SH, van Veldhuisen DJ, Nienhuis HL, van den Berg MP, Hazenberg BP, van der Meer P. Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction? Card Fail Rev. 2020;7(6):e21.","journal-title":"Card Fail Rev"},{"issue":"4","key":"12520_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCULATIONAHA.120.046680","volume":"142","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Dorbala S, Falk RH. Complexities and Pitfalls in Cardiac Amyloidosis. Circulation. 2020;142(4):409\u201315.","journal-title":"Circulation"},{"issue":"10","key":"12520_CR16","doi-asserted-by":"crossref","first-page":"00910","DOI":"10.1016\/j.cpcardiol.2021.100910","volume":"46","author":"A Joury","year":"2021","unstructured":"Joury A, Gupta T, Krim SR. Cardiac Amyloidosis: Presentations, Diagnostic Work-up and Collaborative Approach for Comprehensive Clinical Management. Curr Probl Cardiol. 2021;46(10):00910.","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"12520_CR17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ejh.13679","volume":"107","author":"LL Hester","year":"2021","unstructured":"Hester LL, Gifkins DM, M Bellew K, Vermeulen J, Schecter JM, Strony J, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol. 2021;107(4):428\u201335.","journal-title":"Eur J Haematol."},{"issue":"1","key":"12520_CR18","first-page":"117","volume":"1","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management. Cardio Oncol. 2019;1(1):117\u201330.","journal-title":"Cardio Oncol"},{"issue":"9","key":"12520_CR19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073130","volume":"13","author":"L Obici","year":"2023","unstructured":"Obici L, Callaghan R, Ablett J, Bibiloni C, Bueser T, Concei\u00e7\u00e3o I, et al. Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals. BMJ Open. 2023;13(9): e073130.","journal-title":"BMJ Open"},{"issue":"11","key":"12520_CR20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"12520_CR21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","volume":"132","author":"D Bonderman","year":"2020","unstructured":"Bonderman D, P\u00f6lzl G, Ablasser K, Agis H, Aschauer S, Auer-Grumbach M, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23):742\u201361.","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"12520_CR22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10741-021-10163-0","volume":"27","author":"BW Sperry","year":"2022","unstructured":"Sperry BW, Khoury JA, Raza S, Rosenthal JL. Comprehensive approach to cardiac amyloidosis care: considerations in starting an amyloidosis program. Heart Fail Rev. 2022;27(5):1559\u201365.","journal-title":"Heart Fail Rev"},{"key":"12520_CR23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.hjc.2023.05.004","volume":"73","author":"EA Apostolou","year":"2023","unstructured":"Apostolou EA, Fontrier AM, Efthimiadis GK, Kastritis E, Parissis J, Kanavos P. The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. Hell J Cardiol HJC Hell Kardiologike Epitheorese. 2023;73:73\u201380.","journal-title":"Hell J Cardiol HJC Hell Kardiologike Epitheorese"},{"issue":"4","key":"12520_CR24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cjca.2021.01.015","volume":"37","author":"MK Davis","year":"2021","unstructured":"Davis MK, Fine NM, Small GR, Connolly K, Bosley D, Zieroth S, et al. Establishing a Cardiac Amyloidosis Clinic: A Practical Primer for Cardiologists. Can J Cardiol. 2021;37(4):674\u20138.","journal-title":"Can J Cardiol"},{"issue":"1","key":"12520_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Glob Heart. 2023;18(1):59.","journal-title":"Glob Heart"},{"issue":"13","key":"12520_CR26","volume":"13","author":"N Bumma","year":"2022","unstructured":"Bumma N, Kahwash R, Parikh SV, Isfort M, Freimer M, Vallakati A, et al. Multidisciplinary amyloidosis care in the era of personalized medicine. Front Neurol. 2022;13(13): 935936.","journal-title":"Front Neurol"},{"issue":"4","key":"12520_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cllc.2018.02.001","volume":"19","author":"CJL Stone","year":"2018","unstructured":"Stone CJL, Vaid HM, Selvam R, Ashworth A, Robinson A, Digby GC. Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review. Clin Lung Cancer. 2018;19(4):323-330.e3.","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"12520_CR28","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00381-020-04708-1","volume":"36","author":"H Toledano-Alhadef","year":"2020","unstructured":"Toledano-Alhadef H, Mautner VF, Gugel I, Zipfel J, Haas-Lude K, Constantini S, et al. Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome. Childs Nerv Syst. 2020;36(10):2279\u201384.","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"12520_CR29","first-page":"e2022024","volume":"39","author":"J Kron","year":"2022","unstructured":"Kron J, Syed A, Iden T, Gwathmey K, Polly K, Randolph J, et al. Tackling Health Care Disparities: How to Build a Sarcoidosis Center. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022024.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"12520_CR30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13023-023-02910-3","volume":"18","author":"Y Ando","year":"2023","unstructured":"Ando Y, Waddington-Cruz M, Sekijima Y, Koike H, Ueda M, Konishi H, et al. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. Orphanet J Rare Dis. 2023;18(1):323.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"12520_CR31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12913-017-2340-y","volume":"17","author":"JK Elrod","year":"2017","unstructured":"Elrod JK, Fortenberry JL. Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017;17(1):425.","journal-title":"BMC Health Serv Res"},{"key":"12520_CR32","doi-asserted-by":"crossref","first-page":"117954682110152","DOI":"10.1177\/11795468211015230","volume":"15","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Sarswat N, Fajardo J, Finkel M, Abdulsattar Y, Casta\u00f1o A, et al. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates. Clin Med Insights Cardiol. 2021;15:11795468211015230\u201311795468211015230.","journal-title":"Clin Med Insights Cardiol"},{"issue":"4","key":"12520_CR33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00059-022-05122-w","volume":"47","author":"A H\u00e4nselmann","year":"2022","unstructured":"H\u00e4nselmann A, Berliner D, Bauersachs J, Bavendiek U. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy. Herz. 2022;47(4):324\u201331.","journal-title":"Herz"},{"issue":"4","key":"12520_CR34","first-page":"421","volume":"26","author":"T Fogaren","year":"2022","unstructured":"Fogaren T, Shelton AC, Faller DV, Stull DM, Thuenemann S, Mendelson L. Understanding Amyloidosis: Unraveling the Complexities and Therapeutic Approaches for Oncology Nurses. Clin J Oncol Nurs. 2022;26(4):421\u201332.","journal-title":"Clin J Oncol Nurs"},{"issue":"Suppl 1","key":"12520_CR35","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14-26.","journal-title":"Curr Opin Neurol."},{"issue":"1","key":"12520_CR36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12875-020-01179-w","volume":"21","author":"E Seckler","year":"2020","unstructured":"Seckler E, Regauer V, Rotter T, Bauer P, M\u00fcller M. Barriers to and facilitators of the implementation of multi-disciplinary care pathways in primary care: a systematic review. BMC Fam Pract. 2020;21(1):113.","journal-title":"BMC Fam Pract"},{"issue":"10","key":"12520_CR37","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326.","journal-title":"JBI Evid Synth"},{"issue":"1","key":"12520_CR38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17(1):75.","journal-title":"Implement Sci"},{"key":"12520_CR39","unstructured":"University of Toronto L. A Guide to Comprehensive Searching in the Health Sciences. Available from: https:\/\/guides.library.utoronto.ca\/c.php?g=714472&p=5093471. Cited 2024 Jun 13."},{"issue":"10","key":"12520_CR40","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13296","volume":"50","author":"I Losada","year":"2020","unstructured":"Losada I, Gonz\u00e1lez-Moreno J, Rodriguez A, Uson M, Ripoll-Vera T, Ferrer-Nadal A, et al. Multidisciplinary approach in the management of hATTR. Eur J Clin Invest. 2020;50(10):e13296.","journal-title":"Eur J Clin Invest"},{"issue":"509","key":"12520_CR41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2020.06.029","volume":"1","author":"R Nakov","year":"2020","unstructured":"Nakov R, Sarafov S, Gospodinova M, Kirov A, Chamova T, Todorov T, et al. Transthyretin amyloidosis: Testing strategies and model for center of excellence support. Clin Chim Acta. 2020;1(509):228\u201334.","journal-title":"Clin Chim Acta"},{"key":"12520_CR42","unstructured":"NHS England. 2013\/14 NHS Standard Contract For Diagnostic Service for Amyloidosis (All Ages). London: NHS England; 2013. Report No.: E13\/S(HSS)\/c. Available from: https:\/\/www.england.nhs.uk\/specialised-commissioning-document-library\/service-specifications\/."},{"key":"12520_CR43","unstructured":"Cheng R, Kittleson MM, Wechalekar AD, Alvarez-Cardona J, Mitchell JD, Macedo AVS, et al. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement. Heart. 2024. Available from: https:\/\/heart.bmj.com\/content\/early\/2024\/01\/24\/heartjnl-2023-323502. Cited 2024 May 7."},{"issue":"1","key":"12520_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-021-00646-0","volume":"17","author":"SA Wall","year":"2022","unstructured":"Wall SA, Stevens E, Vaughn J, Bumma N, Rosko AE, Borate U. Multidisciplinary Approach to Older Adults with Hematologic Malignancies\u2014a Paradigm Shift. Curr Hematol Malig Rep. 2022;17(1):31\u20138.","journal-title":"Curr Hematol Malig Rep"},{"key":"12520_CR45","doi-asserted-by":"crossref","unstructured":"Barrios C, S\u00e1nchez-Vanegas G, Villarreal-Garza C, Ossa A, Lombana MA, Monterrosa-Blanco A, et al. Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study. Lancet Reg Health\u2013 Am. 2022;11. Available from: https:\/\/www.thelancet.com\/journals\/lanam\/article\/PIIS2667-193X(22)00071-0\/fulltext. Cited 2023 Sep 29.\u00a0","DOI":"10.1016\/j.lana.2022.100254"},{"issue":"4","key":"12520_CR46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0953-6205(03)00076-1","volume":"14","author":"M Drent","year":"2003","unstructured":"Drent M. Sarcoidosis: benefits of a multidisciplinary approach. Eur J Intern Med. 2003;14(4):217\u201320.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"12520_CR47","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.514","volume":"7","author":"J Duis","year":"2019","unstructured":"Duis J, van Wattum PJ, Scheimann A, Salehi P, Brokamp E, Fairbrother L, et al. A multidisciplinary approach to the clinical management of Prader-Willi syndrome. Mol Genet Genomic Med. 2019;7(3): e514.","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"12520_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clgc.2017.11.004","volume":"16","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, et al. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018;16(3):213\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"12520_CR49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5045\/br.2022.2021227","volume":"57","author":"BZ Maroun","year":"2022","unstructured":"Maroun BZ, Allam S, Chaulagain CP. Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Res. 2022;57(2):106\u201316.","journal-title":"Blood Res"},{"key":"12520_CR50","unstructured":"National Amyloidosis Centre. University College London; 2025. Available from: https:\/\/www.ucl.ac.uk\/amyloidosis\/national-amyloidosis-centre."},{"issue":"1","key":"12520_CR51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43058-020-00023-7","volume":"1","author":"JC Moullin","year":"2020","unstructured":"Moullin JC, Dickson KS, Stadnick NA, Albers B, Nilsen P, Broder-Fingert S, et al. Ten recommendations for using implementation frameworks in research and practice. Implement Sci Commun. 2020;1(1):42.","journal-title":"Implement Sci Commun"},{"issue":"4","key":"12520_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","volume":"31","author":"JN Buxbaum","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M, McPhail ED, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024;31(4):249\u201356. https:\/\/doi.org\/10.1080\/13506129.2024.2405948.","journal-title":"Amyloid"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12520-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:03:35Z","timestamp":1751367815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12520-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12520"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12520-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"415"}}